(redirected from HIV protease inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: deterrent
References in periodicals archive ?
In light of the level of use overseas, Chugai applied to the Ministry of Health, Labour and Welfare on July 20 2006 for manufacturing and marketing approval of INVIRASE(R) Tablet 500 mg for concomitant use with HIV protease inhibitor ritonavir and an additional drug form.
Caution should be exercised if HIV protease inhibitors, including INVIRASE, are used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (eg, atorvastatin).
HIV protease inhibitors block the HIV protease enzyme, yielding copies of HIV that cannot infect new cells.
We are very pleased with the "forced resistance" data from the collaborative study with Professor Wainberg's group on our lead HIV protease inhibitor PPL-100, as this complements the cross-resistance study reported last February by Procyon", said Hans J.
We are pleased with the solid safety profile of our PPL-100 HIV protease inhibitor as this is a critical issue in the development of such compounds," said Hans Mader, president and CEO of Procyon Biopharma.
The Food and Drug Administration's fast track designation for 640385 highlights the productive collaboration between Vertex and GlaxoSmithKline, which has generated three novel HIV protease inhibitor product candidates over the past 12 years, and has established both companies as leaders in the development of new drugs to treat HIV infection," said Joshua Boger, Ph.
Originally approved by the FDA in 1995, the introduction of INVIRASE as the first HIV protease inhibitor represented a major milestone in the treatment of HIV/AIDS.
Risk factors for fat accumulation are: duration of therapy, CD4 T-cell count, viral load, age, exposure to HIV protease inhibitors (PIs), and female sex.
Researchers at San Francisco General Hospital and the Howard Hughes Institute tested seven HIV protease inhibitors activity.
Though the study did not include HIV+ patients, the combination of erythromycin and HIV protease inhibitors could be very dangerous.
Using insights gained in the design of HIV protease inhibitors, scientists at Boehringer Ingelheim in Germany discovered BILN 2061, a potent and selective inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 (NS3) serine protease.